Adargiminase
Adargiminase (NEI-01) is a modified arginine-depleting enzyme and albumin binder. Adargiminase catalyzes the conversion of arginine to citrulline and ammonia, reduces plasma arginine levels to undetectable levels, and binds to serum albumin from Mus musculus (mouse), Rattus norvegicus (rat), Canis lupus familiaris (dog) and Homo sapiens (human) to extend its half-life. Adargiminase inhibits the viability of ASS1-negative pancreatic cancer cells, and reduces tumor volume and weight. Adargiminase can be used for the research of pancreatic cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
Adargiminase (0.001-10 μg/mL; 72 h) potently inhibits the viability of ASS1-negative MIA PaCa-2 and PANC-1 pancreatic cancer cells, but exerts no inhibitory effect on ASS1-positive SMMC7721 hepatocellular carcinoma cells[1].
Adargiminase (0.1 μg/mL; 6-96 h) induces activation of the autophagy pathway (increased levels of LC3-II, Beclin 1, and phosphorylated AMPKα) and activation of the apoptosis pathway (decreased level of PARP-1) in MIA PaCa-2 pancreatic cancer cells[1].
Adargiminase (0.001-1 μg/mL; 72 h) has no effect on NEI-01-adapted MIA PaCa-2 pancreatic cancer cells, but resensitizes these cells after 96 h of culture in NEI-01-free medium[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human pancreatic cancer cell lines (MIA PaCa-2, PANC-1), human hepatocellular carcinoma cell line (SMMC7721)
-
Concentration:0.001-10 μg/mL
-
Incubation Time:72 h
-
Result:Inhibited viability of ASS1-negative MIA PaCa-2 cells with an IC50 of 0.086 μg/mL.
Inhibited viability of ASS1-negative PANC-1 cells with an IC50 of 0.190 μg/mL.
Showed no significant inhibition of ASS1-positive SMMC7721 cells, with an IC50 >10 μg/mL.
-
Cell Line:MIA PaCa-2 human pancreatic cancer cell line
-
Concentration:0.1 μg/mL
-
Incubation Time:6-96 h
-
Result:Increased levels of LC3-II, Beclin 1, and phospho-AMPKα.
Decreased levels of PARP-1.
Indicated activation of both autophagic and apoptotic pathways.
-
Cell Line:NEI-01-adapted and washout MIA PaCa-2 human pancreatic cancer cell line
-
Concentration:0.001-1 μg/mL
-
Incubation Time:72 h
-
Result:Showed resistance to NEI-01 treatment in NEI-01-adapted MIA PaCa-2 cells.
Resensitized washout MIA PaCa-2 cells to NEI-01 with an IC50 of 0.012 μg/mL.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c female athymic nude mice (4-6-week-old; pancreatic cancer xenograft model)[1]
-
Dosage:2 U; 5 U
-
Administration:i.p.; twice a week
-
Result:Significantly reduced tumor volume compared to control (2 U dose).
Significantly reduced tumor volume (p < 0.01) and tumor weight (p = 0.004) compared to control (5 U dose).
Reduced plasma arginine levels over the course of the experiment.
Induced only a very slight increase in ASS1 expression in tumor tissue.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
化学情報
-
SMILES
[Adargiminase]
-
別名
NEI-01
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Adargiminase 関連分類
製品番号: HY-P992098
Powered by Bioz
- Adargiminase
- NEI-01
- NEI01
- NEI 01
- Protein Arginine Deiminase
- human pancreatic mouse xenograft models
- dog serum albumin
- rat serum albumin
- ASS1-negative pancreatic cancer cells
- mouse serum albumin
- MIA PaCa-2 pancreatic cancer cells
- autophagic pathways
- ASS1-positive SMMC7721 hepatocellular carcinoma cells
- apoptotic pathways
- PANC-1 pancreatic cancer cells
- Inhibitor
- inhibitor
- inhibit